Cerebral Infarction Clinical Trial
— Xe-SAHOfficial title:
Effect of Xenon on Brain Injury, Neurological Outcome and Survival in Patients After Aneurysmal Subarachnoid Hemorrhage
An investigator-initiated clinical drug study Main Objective: To explore neuroprotective properties of xenon in patients after aneurysmal subarachnoid hemorrhage (SAH). Primary endpoint: Global fractional anisotropy of white matter of diffusion tensor imaging (DTI). Hypothesis: White matter damage is less severe in xenon treated patients, i.e. global fractional anisotropy is significantly higher in the xenon group than in the control group as assessed with the 1st magnetic resonance imaging (MRI). After confirmation of aSAH and obtaining a signed assent subjects will be randomized to the following groups: Control group: Standard of Care (SOC) group: Air/oxygen and Normothermia 36.5-37.5°C; Xenon group: Normothermia 36.5-37.5°C +Xenon inhalation in air/oxygen for 24 hours. Brain magnetic resonance imaging techniques will be undertaken to evaluate the effects of the intervention on white and grey matter damage and neuronal loss. Neurological outcome will be evaluated at 3, 12 and 24 months after onset of aSAH symptoms Investigational drug/treatment, dose and mode of administration: 50±2 % end tidal concentration of inhaled xenon in oxygen/air. Comparative drug(s)/placebo/treatment, dose and mode of administration: Standard of care treatment according to local and international consensus reports. Duration of treatment: 24 hours Assessments: Baseline data Information that characterizes the participant's condition prior to initiation of experimental treatment is obtained as soon as is clinically reasonable. These include participant demographics, medical history, vital signs, oxygen saturation, and concentration of oxygen administered. Acute data The collected information will contain quantitative and qualitative data of aSAH patients, as recommended by recent recommendations of the working group on subject characteristics, and including all relevant Common Data Elements (CDE) can be applied. Specific definitions, measurements tools, and references regarding each SAH CDE can be found on the weblink here: https://www.commondataelements.ninds.nih.gov/SAH.aspx#tab=Data_Standards.
Status | Not yet recruiting |
Enrollment | 160 |
Est. completion date | December 31, 2027 |
Est. primary completion date | December 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: To be considered eligible to participate in this study, a SAH subject must meet the inclusion criteria listed below: 1. Informed consent obtained from the next of kin or legal representative 2. Aneurysmal subarachnoid hemorrhage visible on CTA or DSA. 3. Deterioration of consciousness to Hunt-Hess 3-5 4. Age of = 18 years 5. Intubated. 6. GCS 3-12 obtained off neuromuscular blocking agents 7. Xenon treatment can be started within 6 hours after onset of SAH symptoms Exclusion Criteria: An aSAH subject may not be enrolled in the trial if he/she meets any one of the exclusion criteria below: 1. Acute or chronic traumatic brain injury 2. Maximum diameter of intracerebral hemorrhage > 2.5 cm 3. Pneumothorax or pneumomediastinum, 4. Acute lung injury requiring = 60% FIO2 (fraction of inspired oxygen). 5. Systolic arterial pressure < 80 mmHg or mean arterial pressure < 60 mmHg for over 30 min period 6. Bilaterally fixed and dilated pupils 7. Positive pregnancy test, known pregnancy, or current breast-feeding 8. Neurological deficiency due to traumatic brain injury or other neurological illness 9. Imminent death or current life-threatening disease 10. Current enrollment in another interventional study 11. The subject is known to have clinically significant laboratory abnormality, medical condition (such as decompensated liver disease or severe chronic obstructive pulmonary disease), or social circumstance that, in the investigator's opinion, makes it inappropriate for the subject to participate in this clinical trial. 12. Presence of implants or foreign bodies which are not known to be MRI safe |
Country | Name | City | State |
---|---|---|---|
Finland | Aalto University School of Science | Helsinki | |
Finland | Kuopio University Hospital | Kuopio | |
Finland | Tampere University Hospital | Tampere | |
Finland | Elomatic | Turku | |
Finland | Turku University Hospital | Turku | |
Finland | University of Turku, Turku Bioscience, Analysis of the metabolomics | Turku | |
Sweden | Örebro University | Örebro |
Lead Sponsor | Collaborator |
---|---|
Turku University Hospital | Academy of Finland |
Finland, Sweden,
Arola O, Saraste A, Laitio R, Airaksinen J, Hynninen M, Backlund M, Ylikoski E, Wennervirta J, Pietila M, Roine RO, Harjola VP, Niiranen J, Korpi K, Varpula M, Scheinin H, Maze M, Vahlberg T, Laitio T; Xe-HYPOTHECA Study Group. Inhaled Xenon Attenuates My — View Citation
Laitio R, Hynninen M, Arola O, Virtanen S, Parkkola R, Saunavaara J, Roine RO, Gronlund J, Ylikoski E, Wennervirta J, Backlund M, Silvasti P, Nukarinen E, Tiainen M, Saraste A, Pietila M, Airaksinen J, Valanne L, Martola J, Silvennoinen H, Scheinin H, Har — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fractional anisotropy of the white matter | Global fractional anisotropy of white matter of diffusion tensor imaging (DTI). Hypothesis: White matter damage is less severe in xenon treated patients, i.e. global fractional anisotropy is significantly higher in the xenon group than in the control group as assessed with the 1st MRI. | 48-96 hours after start of aSAH symptoms | |
Secondary | Fractional anisotropy of white matter at cerebellum and/or at corpus callosum as assessed with the 1st MRI. | Fractional anisotropy of white matter at cerebellum and/or at corpus callosum as assessed with the 1st MRI. | 48-96 hours after start of aSAH symptoms | |
Secondary | Safety and tolerability of xenon | Safety and tolerability of xenon as assessed with a ratio of adverse events, serious adverse events and suspected unexpected serious adverse reactions (SUSARs) during the follow-up of one year between the xenon group and the control group. | during the follow-up of one year | |
Secondary | Composite of radiological early brain injury (EBI) and delayed cerebral ischemia (DCI) | Composite of radiological EBI (within 72 hours after start of SAH symptoms) and DCI (Criterion of DCI: 1. a new focal neurological deficit (such as hemiparesis, aphasia, apraxia, hemianopia, or neglect) /decrease in level of consciousness (i.e. decrease of at least 2 points on the Glasgow Coma Scale; either on the total score or on one of its individual components, such as eye, motor on either side, or verbal). This should last for at least 1 hour and not is due to other causes (e.g. hydrocephalus, seizures, metabolic derangement, infection, sedation) and is not apparent immediately after aneurysm occlusion, and cannot be attributed to other causes by means of clinical assessment, CT or MRI scanning of the brain, and appropriate laboratory studies, 2. a new infarct on follow-up imaging (i.e. in any of the following: 2nd MRI, CT, CTA, DSA and perfusion CT) after 4 days post-SAH, or 3. both 1 and 2), and poor outcome at 3-months (good: mRS 0-2; poor: mRS 3-6) at 3-months and at 1 year | EBI: within first 72 hours after start of aSAH symptoms; mRS at 3 months and at 1 year and at 2 years after onset of aSAH symptoms | |
Secondary | Neurogenic Stress Cardiomyopathy and Stunned Myocardium | Neurogenic Stress Cardiomyopathy and Stunned Myocardium (i.e. myocardial injury caused by sympathetic storm and autonomic dysregulation with hs-troponin elevation, left ventricular dysfunction or ECG changes) | follow-up of 1 year | |
Secondary | Intracerebral pressure (ICP) | ICP level
Duration of therapy for ICP control/monitoring |
during ICU stay up to 14 days after onset of aSAH symptoms | |
Secondary | Intracerebral pressure (ICP) | Need for ICP therapies (hypothermia, decompressive craniotomy) | during ICU stay up to 14 days after onset of aSAH symptoms | |
Secondary | Intracerebral pressure (ICP) | Duration of therapy for ICP control/monitoring | during ICU stay up to 14 days after onset of aSAH symptoms | |
Secondary | Plasma catecholamine level | Plasma level of noradrenaline , adrenaline, and dopamine | within 3 hours of ICU arrival, at 24h, 48h and 72 h after onset of aSAH symptoms | |
Secondary | Selected biomarkers | Selected biomarkers of brain injury: neurofilament light (NF-L), glial fibrillary acidic protein (GFAP), calcium binding protein S100B (S100B), ubiquitin carboxyterminal hydrolase L1 (UCH-L1), total tau, cytokines (tumour necrosis factor alpha, interleukins 6 and 10) | within 3 hours of ICU arrival and at 24h, at 48h and at 72h after onset of aSAH symptoms | |
Secondary | Development of prognostication models | Development of prognostication models with a selected combination of brain imaging, clinical data, biomarkers and metabolomics by applying artificial intelligence and machine learning for long-term outcome after aSAH | long-term outcome at 3 months, at 1 and at 2 years after onset of aSAH symptoms | |
Secondary | Development of prognostication models | Development of prognostication models with a selected combination of brain imaging, clinical data, biomarkers and metabolomics by applying artificial intelligence and machine learning for DCI after aSAH | between day 4 and 6 weeks after onset of aSAH symtoms | |
Secondary | Development of prognostication models | Development of prognostication models with a selected combination of brain imaging, clinical data, biomarkers and metabolomics by applying artificial intelligence and machine learning for vasospasm after aSAH | within 21 days after onset of aSAH symptoms | |
Secondary | Development of prognostication models | Development of prognostication models with a selected combination of brain imaging, clinical data, biomarkers and metabolomics by applying artificial intelligence and machine learning for EBI after aSAH | within 72 hours after onset of aSAH symtoms | |
Secondary | Difference of MRI parameters between xenon and control group | Difference of MRI parameters (fractional anisotropy, axial diffucivity, radial diffucivity of diffusion tensor imaging, DTI) between xenon and control group and in predicting risk for EBI | within 72 hours after onset of aSAH symptoms | |
Secondary | Difference of MRI parameters between xenon and control group | Difference of MRI parameters (fractional anisotropy, axial diffucivity, radial diffucivity of DTI) between xenon and control group and in predicting risk for vasospasm | within 21 days after onset of aSAH symptoms | |
Secondary | Difference of MRI parameters between xenon and control group | Difference of MRI parameters (fractional anisotropy, axial diffucivity, radial diffucivity of DTI) between xenon and control group and in predicting risk for DCI | between day 4 and 6 weeks after onset of aSAH symptoms | |
Secondary | Difference of MRI parameters between xenon and control group | Difference of MRI parameters (fractional anisotropy, axial diffucivity, radial diffucivity of DTI) between xenon and control group and in predicting risk for good/poor neurological outcome at 3 moths, at 1 year and at 2 years after onset of aSAH symptoms (mRS 0-2/mRS 3-6). | at 3 months, at 1 year and at 2 years after onset of aSAH symptoms | |
Secondary | Difference of CTA findings | Difference of CTA ischemic findings between xenon and control group and in predicting risk for EBI | within 72 hours after onset of aSAH symptoms | |
Secondary | Difference of CTA findings | Difference of ischemic findings in CTA between xenon and control group and in predicting risk for vasospasm | within 21 days after onset of aSAH symptoms | |
Secondary | Difference of CTA findings | Difference of ischemic findings in CTA between xenon and control group and in predicting risk for DCI | between day 4 and 6 weeks after onset of aSAH symptoms | |
Secondary | Difference of CTA findings between xenon and control group | Difference of ischemic findings in CTA between xenon and control group and in predicting risk for good/poor neurological outcome at 3 moths, at 1 year and at 2 years after onset of aSAH symptoms (mRS 0-2/mRS 3-6). | at 3 months, at 1 year and at 2 years after onset of aSAH symptoms | |
Secondary | Difference of DSA findings between xenon and control group | Difference of DSA findings indicating ischemic pattern of perfusion between xenon and control group and in predicting risk for EBI | within 72 hours after onset of aSAH symptoms | |
Secondary | Difference of DSA findings between xenon and control group | Difference of DSA findings indicating ischemic pattern of perfusion between xenon and control group and in predicting risk for vasospasm | within 21 days after onset of aSAH symptoms | |
Secondary | Difference of DSA findings between xenon and control group | Difference of DSA findings indicating ischemic pattern of perfusion between xenon and control group and in predicting risk for DCI | between day 4 and 6 weeks after onset of aSAH symptoms | |
Secondary | Difference of DSA findings between xenon and control group | Difference of DSA findings indicating ischemic pattern of perfusion between xenon and control group and in predicting risk for good/poor neurological outcome at 3 moths, at 1 year and at 2 years after onset of aSAH symptoms (mRS 0-2/mRS 3-6). | at 3 months, at 1 year and at 2 years after onset of aSAH symptoms | |
Secondary | Activity of microglia cells assessed with PET | It will be explored whether [11C](R)-PK11195 can be used to test the hypothesis of neuroprotective effect of xenon and to explore the role of inflammatory process for DCI after SAH. This could be demonstrated by showing less microglial activation in xenon group than in the reference therapy group and in the patients with good outcome, i.e. no DCI; Difference of activity of microglia cells between xenon and control group and in predicting risk for DCI | DCI between day 4 and 6 weeks after onset of aSAH symptoms; The 1st PETscan 4 ±1 weeks after onset of aSAH symptoms and the 2nd scan at 3 months after onset of SAH symptoms. | |
Secondary | Activity of microglia cells assessed with PET | It will be explored whether [11C](R)-PK11195 can be used to test the hypothesis of neuroprotective effect of xenon and to explore the role of inflammatory process for neurological outcome after SAH. This could be demonstrated by showing less microglial activation in xenon group than in the reference therapy group and in the patients with good outcome, i.e. mRS 0-2; | The 1st scan at 4 ±1 weeks after and the 2nd scan at 3 months after onset of SAH symptoms. Outcome: at 3 months, at 1 year and at 2 years after onset of aSAH symptoms | |
Secondary | Cerebral fluid dynamics | Predictive value of CFD simulations assessed with 3 dimensional DSA within 4 days of ICU arrival in predicting risk for EBI within 72 hours after onset of aSAH symptoms | Measures performed within 72 hours of ICU arrival | |
Secondary | Cerebral fluid dynamics | Predictive value of CFD simulations assessed with 3 dimensional DSA within 21 days of ICU arrival in predicting risk for neurological outcome at 3 months, at 1 year and at 2 years after SAH (mRS 0-2) | Measures performed within 21 days of ICU arrival; outcome at 3 months, at 1 year and at 2 years after onset of aSAH symptoms | |
Secondary | Cerebral fluid dynamics | Predictive value of CFD simulations assessed with 3 dimensional DSA within 21 days of ICU arrival in predicting risk for DCI within 6 weeks after onset of aSAH symptoms | Measures performed within 21 days of ICU arrival; DCI within 6 weeks after onset of aSAH symptoms |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02551003 -
Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy
|
Phase 1/Phase 2 | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT00684515 -
Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)
|
Phase 2 | |
Not yet recruiting |
NCT04082091 -
Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
|
||
Completed |
NCT01915368 -
Determining Optimal Post-Stroke Exercise (DOSE)
|
N/A | |
Terminated |
NCT01684462 -
The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke
|
Phase 2 | |
Completed |
NCT00386191 -
Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment
|
Phase 4 | |
Completed |
NCT00004734 -
Vitamin Therapy for Prevention of Stroke
|
Phase 3 | |
Completed |
NCT02684825 -
Detection of Silent Atrial Fibrillation aFter Ischemic StrOke
|
N/A | |
Completed |
NCT02248233 -
Nimodipine for Treating Acute Massive Cerebral Infarction
|
Phase 4 | |
Completed |
NCT02963545 -
TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke
|
N/A | |
Completed |
NCT02511249 -
Early Determinants of Multidimensional Outcome at School Age After Neonatal Arterial Ischemic Stroke
|
N/A | |
Completed |
NCT02101606 -
Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke
|
Phase 2 | |
Completed |
NCT00829361 -
Stroke Telemedicine for Arizona Rural Residents Trial
|
N/A | |
Completed |
NCT01500421 -
Safty and Feasibility Study of Therapeutic Cooling in Acute Ischemic Stroke (COOLAID Øresund)
|
Phase 2 | |
Recruiting |
NCT01003470 -
Treating Apoplectic Sequela With Acupuncture: a Randomized Controlled Study
|
Phase 2 | |
Terminated |
NCT00331890 -
ICTUS Study: International Citicoline Trial on Acute Stroke
|
Phase 3 | |
Completed |
NCT03741400 -
Virtual Reality Glove for Hand and Arm Rehabilitation After Stroke
|
N/A | |
Recruiting |
NCT04908241 -
Telerehabilitation With Aims to Improve Lower Extremity Recovery Post-Stroke (TRAIL-RCT)
|
N/A |